CAR T‐cell therapy for pancreatic cancer

Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenv...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of surgical oncology Ročník 116; číslo 1; s. 63 - 74
Hlavní autori: DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Wiley Subscription Services, Inc 01.07.2017
Predmet:
adoptive cell therapy
Antigens, Neoplasm - immunology
Cancer surgery
CAR T cells
Carcinoembryonic Antigen - immunology
CD24 Antigen - immunology
checkpoint blockade
chimeric antigen receptor
Clinical Trials as Topic
GPI-Linked Proteins - immunology
Humans
immunotherapy
Immunotherapy, Adoptive
Mesothelin
Mucin-1 - immunology
Neoplasm Proteins - immunology
Pancreatic cancer
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Receptor, ErbB-2 - immunology
Receptors, Antigen, T-Cell
Receptors, Natural Killer Cell - immunology
Stromal Cells - immunology
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Transplantation Conditioning
checkpoint blockade
chimeric antigen receptor
CAR T cells
adoptive cell therapy
immunotherapy
ISSN:0022-4790, 1096-9098, 1096-9098
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T‐cell therapy.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0022-4790
1096-9098
1096-9098
DOI:10.1002/jso.24627